Compare TG Therapeutics Inc (TGTX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Xylem, Inc. — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Xylem, Inc. is far larger — about 3.5× TG Therapeutics Inc's market cap, and Xylem, Inc. pays a 1.43% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | XYL | |
|---|---|---|
Market Cap | $8.26B | $28.67B |
Sector | Health | Industrials |
52-Week High | $59.06 | $152.95 |
52-Week Low | $26.39 | $106.34 |
Enterprise Value | $8.50B | $29.92B |
Dividend Yield | — | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
